MedTrace Logo

Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study

NCT03170219 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-01-23

Study results available
· View outcomes & findings →

Summary

To determine if a strategy of early discharge using a novel subcutaneous delivery system for parenteral furosemide can improve clinical outcomes within 30 days of randomization (days alive and outside the hospital) compared to usual care.

Conditions

  • Acute Heart Failure
  • Decompensated Heart Failure

Interventions

COMBINATION_PRODUCT

subcutaneous furosemide and sc2wear device

subcutaneous furosemide administered via sc2wear device vs. standard of care

Sponsors & Collaborators

  • Adrian Hernandez

    lead OTHER

Principal Investigators

  • Adrian Hernandez, MD · Duke University

  • Eugene Braunwald, MD · Harvard University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-27
Primary Completion
2018-09-20
Completion
2018-09-20
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03170219 on ClinicalTrials.gov